1033 related articles for article (PubMed ID: 23590898)
61. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009.
Morfin-Otero R; Dowzicky MJ
Clin Ther; 2012 Jan; 34(1):101-12. PubMed ID: 22177546
[TBL] [Abstract][Full Text] [Related]
62. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Mendes RE; Jones RN
Int J Antimicrob Agents; 2016 Aug; 48(2):144-50. PubMed ID: 27291285
[TBL] [Abstract][Full Text] [Related]
63. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001).
Streit JM; Jones RN; Sader HS; Fritsche TR
Int J Antimicrob Agents; 2004 Aug; 24(2):111-8. PubMed ID: 15288308
[TBL] [Abstract][Full Text] [Related]
64. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
Tsao SM; Lin HC; Lee CM; Hsu GJ; Chen CM; Sun W; Liu YC; Jang TN; Cheng YJ; Lu PL; Chiang PC; Wang LS; Kung HC; Chuang YC; Shi ZY; Liu JW; Huang CH; Lu CT; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S184-7. PubMed ID: 19013352
[TBL] [Abstract][Full Text] [Related]
65. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016].
Wang X; Zhao C; Li H; Chen H; Jin L; Wang Z; Liao K; Zeng J; Xu X; Jin Y; Su D; Liu W; Hu Z; Cao B; Chu Y; Zhang R; Luo Y; Hu B; Wang H
Sheng Wu Gong Cheng Xue Bao; 2018 Aug; 34(8):1205-1217. PubMed ID: 30152206
[TBL] [Abstract][Full Text] [Related]
66. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
Fernández-Canigia L; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
[TBL] [Abstract][Full Text] [Related]
67. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial.
Waites KB; Duffy LB; Dowzicky MJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3479-84. PubMed ID: 17005838
[TBL] [Abstract][Full Text] [Related]
68. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
69. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
Pankey GA; Ashcraft DS
Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
[TBL] [Abstract][Full Text] [Related]
70. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
Zarakolu P; Hasçelik G; Unal S
Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
[TBL] [Abstract][Full Text] [Related]
71. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
[TBL] [Abstract][Full Text] [Related]
72. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases.
Biedenbach DJ; Beach ML; Jones RN
Diagn Microbiol Infect Dis; 2001 Aug; 40(4):173-7. PubMed ID: 11576790
[TBL] [Abstract][Full Text] [Related]
73. Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Lu PL; Liu YC; Toh HS; Lee YL; Liu YM; Ho CM; Huang CC; Liu CE; Ko WC; Wang JH; Tang HJ; Yu KW; Chen YS; Chuang YC; Xu Y; Ni Y; Chen YH; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S37-43. PubMed ID: 22749057
[TBL] [Abstract][Full Text] [Related]
74. Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria.
Jones RN; Wilson ML; Weinstein MP; Stilwell MG; Mendes RE
Diagn Microbiol Infect Dis; 2013 Apr; 75(4):402-5. PubMed ID: 23514756
[TBL] [Abstract][Full Text] [Related]
75. Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years.
Yang Q; Xu YC; Kiratisin P; Dowzicky MJ
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):314-323. PubMed ID: 28951056
[TBL] [Abstract][Full Text] [Related]
76. [Surveillance of antimicrobial resistance among nosocomial gram-negative pathogens from 15 teaching hospitals in China in 2005].
Yang QW; Xu YC; Chen MJ; Hu YJ; Ni YX; Sun JY; Yu YS; Kong HS; He L; Wu WY; Ye HF; Yang YM; Zhu LN; Guo SH; Ji P; Zhu ZH; Ren JK; Zhang LX; Sun ZY; Zhu XH; Tong MQ; Zhao WS; Mei YN; Liu Y; Zhang ZJ; Duan Q; Li D; Liu PP; Wang J; Han LX; Wang H; Xie XL
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2753-8. PubMed ID: 18167265
[TBL] [Abstract][Full Text] [Related]
77. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
78. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
Pillar CM; Aranza MK; Shah D; Sahm DF
J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
[TBL] [Abstract][Full Text] [Related]
79. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
80. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Jia P; Zhu Y; Zhang H; Cheng B; Guo P; Xu Y; Yang Q
BMC Microbiol; 2022 Oct; 22(1):234. PubMed ID: 36182895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]